Celerion Achieves Milestone With CLIA Certification for Bioanalytical Laboratory
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leading clinical research organization, has been recognized for the eighth consecutive year as the winner of a CRO Leadership Award by global biopharmaceutical executives in Clinical Leader and Life Science Leader’s annual CRO Leadership Awards for 2023.
Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has expanded its molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice (GLP/GCP) standards to support the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in both of the company’s Lincoln and Zürich bioanalytical laboratories and includes ELISpot analysis, flow cytometry, and qPCR.
Celerion Expands Its Service Offering to Include GLP/GCP Compliant Molecular and Cell Biology Testing
MIAMI--(BUSINESS WIRE)--H.I.G. Capital (“H.I.G.”), a leading global investment firm with $52 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of Celerion Holdings, Inc. (“Celerion” or the “Company”), a leading full-service provider of outsourced clinical research services to the pharmaceutical industry.
Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services. This investment includes expanding laboratory space, and adding new capabilities as well as a dedicated customer service team.
LINCOLN, Neb., April 6, 2022 /PRNewswire/ -- Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, has announced that it has made a significant investment in its ADME (Absorption, Distribution, Metabolism and Excretion) suite of services to meet continuously increasing demand to conduct these studies. This investment includes expanding laboratory space, adding new capabilities as well as a dedicated customer service team.
Celerion, a CRO to the biopharmaceutical industry, has completed additions to its research capacity and services, including a new Screening and Return Center, upgraded pharmacy compounding suites, expanded Absorption, Distribution, Metabolism and Excretion (ADME) lab capacity and fifty additional beds.
LINCOLN, Neb., Oct. 9, 2020 /PRNewswire/ -- Celerion, a leading clinical research organization (CRO) provider to the biopharmaceutical industry, will deliver a key address on the final day of the Veeva R&D and Quality Summit, being held online October 13-14, 2020. The annual event brings together pharmaceutical, biotech and medical device & diagnostics leaders to discuss the latest innovations in the industry.
ZURICH--(BUSINESS WIRE)--Celerion announced today the expansion of specialized high-resolution mass spectrometry (HR-MS) profiling capabilities demonstrating their commitment to further assisting sponsors in meeting the regulatory requirements to characterize and quantify drug metabolites and their potential for impacting drug effect as part of the process to becoming an approved therapeutic product.